Kidney Cancer, Melanoma (Skin)
Conditions
Keywords
recurrent renal cell cancer, stage IV renal cell cancer, recurrent melanoma, stage IV melanoma
Brief summary
RATIONALE: Denileukin diftitox may be able to make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with metastatic melanoma or metastatic kidney cancer.
Detailed description
OBJECTIVES: Primary * Determine the clinical response in patients with metastatic melanoma or metastatic kidney cancer treated with denileukin diftitox. Secondary * Determine whether changes occur in levels of CD4-positive CD25-positive lymphocytes in the peripheral blood of these patients before and after treatment with this drug. * Determine the toxicity profile of this drug in these patients. OUTLINE: Patients are stratified according to disease type (metastatic melanoma vs metastatic kidney cancer). Patients receive denileukin diftitox IV over 1 hour on days 1-5, 21-25, 42-46, and 63-67. Treatment repeats every 84 days (12 weeks) for up to a maximum total of 5 courses in the absence of disease progression, autoimmune ocular toxicity attributable to denileukin diftitox, or any other unacceptable toxicity. At any time during therapy, patients achieving a complete response receive 1 additional course of therapy after the complete response. PROJECTED ACCRUAL: A total of 10-96 patients (5-48 per stratum) will be accrued for this study within 3-4 years.
Interventions
BIOLOGICALdenileukin diftitox
Sponsors
National Cancer Institute (NCI)
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Melanoma * Kidney cancer * Metastatic disease * Measurable disease * Documented disease progression while receiving standard therapy * No resectable local or regional disease PATIENT CHARACTERISTICS: Age * 16 and over Performance status * ECOG 0-2 Life expectancy * More than 3 months Hematopoietic * WBC ≥ 3,000/mm\^3 * Platelet count ≥ 90,000/mm\^3 * Lymphocyte count ≥ 500/mm\^3 * No concurrent coagulation disorders Hepatic * Bilirubin ≤ 2.0 mg/dL (\< 3.0 mg/dL for patients with Gilbert's syndrome) * AST and ALT \< 3 times normal * Albumin ≥ 2.5 g/dL * Hepatitis B surface antigen negative * Hepatitis C antibody negative Renal * Creatinine ≤ 2.0 mg/dL Cardiovascular * Normal thallium stress test\* * No prior myocardial infarction * No history of severe coronary artery disease * No major medical illness of the cardiovascular system NOTE: \*For patients \> 50 years of age OR who have a history of cardiovascular disease Pulmonary * No major medical illness of the respiratory system Immunologic * HIV negative * No active systemic infection * No presence of opportunistic infections * No primary or secondary immunodeficiency * No autoimmune disease * No other known immunodeficiency Other * No sensitivity to denileukin diftitox or any of its components (e.g., diphtheria toxin, interleukin-2, or excipients) * Willing to undergo leukapheresis * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy * Prior treatment with interleukin-2 allowed provided the patient's disease status required this therapy Chemotherapy * Recovered from prior chemotherapy Endocrine therapy * No concurrent systemic steroids Radiotherapy * Recovered from prior radiotherapy Surgery * Not specified Other * More than 3 weeks since prior systemic anticancer therapy * No other concurrent systemic anticancer therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in levels of CD4-positive CD25-positive lymphocytes in the peripheral blood | — |
| Toxicity | — |
Countries
United States
Outcome results
None listed